In re Appraisal of SWS Group, Inc.

IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE

IN RE APPRAISAL OF SWS GROUP, ) C.A. No. 10554-VCG
INC. )

MEMORANDUM OPINION

Date Submitted: February 27, 2017
Date Decided: May 30, 2017

Marcus E. Montejo, Kevin H. Davenport, Eric J. Juray, Chaz L. Enerio, of
PRICKETT, JONES & ELLIOTT, P.A., Wilmington, Delaware, Attorneys for
Petitioners Merlin Partners, LP and AAMAF, LP.

Kurt M. Heyman, Patricia L. Enerio, Melissa N. Donimirski, of HEYMAN ENERIO
GATTUSO & HIRZEL LLP, Wilmington, Delaware, Attorneys for Petitioners Lone
Star Value Investors, LP and Lone Star Value Co-Invest II, LP.

Garrett B. Moritz, Eric D. Selden, Nicholas D. Mozal, of ROSS ARONSTAM &
MORITZ LLP, Wilmington, Delaware; OF COUNSEL: William Savitt, Andrew J.H.
Cheung, Noah B. Yavitz, of WACHTELL, LIPTON, ROSEN & KATZ, New York,
New York, Attorneys for Respondents SWS Group, Inc. and Hilltop Securities
Holdings LLC.

GLASSCOCK, Vice Chancellor
 The Petitioners here are former stockholders of SWS Group Inc. (“SWS” or

the “Company”), a Delaware corporation. They are seeking a statutory appraisal of

their shares. The Company was exposed to the market in a sales process. As this

Court has noted, most recently in In Re Appraisal of Petsmart, Inc.,1 a public sales

process that develops market value is often the best evidence of statutory “fair value”

as well. As noted below, however, the sale of SWS was undertaken in conditions

that make the price thus derived unreliable as evidence of fair value, in my opinion.

Methods of valuation derived from comparable companies are similarly unreliable

here. I rely, therefore, on a discounted cash flow (“DCF”) analysis to determine the

fair value of SWS, assisted by the learned but divergent opinions of the parties’

experts. My rationale for rejecting sale price, and my resolution of the disputed

issues involved in the competing DCFs, follows.

This action arises from the Petitioners’ statutory right to receive a judicial

determination of the fair value of their shares of SWS. On January 1, 2015, SWS

merged into a wholly-owned subsidiary of Hilltop Holdings, Inc. (“Hilltop”), itself

a substantial creditor of SWS. SWS shareholders received a mix of cash and stock

worth $6.92. The Petitioners are a series of funds holding appraisal-eligible shares

of SWS. The Petitioners bring this action challenging the merger consideration as

1
In Re Appraisal of Petsmart, Inc., 2017 WL 2303599 (Del. Ch. May 26, 2017).

1
unfair. It is my statutory duty to determine the fair value of the Petitioners’ shares

as of the date of the merger.

This case presents two divergent narratives. The first is that the Company was

on the brink of a turnaround before the sale, and had only been suffering due to

unique and unprecedented market conditions. The second is that the Company had

fundamental structural problems making it difficult to compete at its size. The

reality is somewhere in the middle, in my view. The Company was a struggling

bank which had a chance to modestly improve its outlook around the time of sale.

It still faced a long climb, however.

Similarly, this case presents two divergent expert valuations. Neither party

attempts to invoke the deal price, but for different reasons. The Petitioners argue

that the sales process was so hopelessly flawed that the deal price is irrelevant. The

Respondents argue that the deal price is improper here because it includes large

synergies inappropriate to statutory fair value. Accordingly, neither party relies on

price—though the Respondents argue any valuation should be reconciled or checked

against the deal price. Each side instead relies on traditional valuation methods.

Those traditional valuation methodologies result in almost mirror image valuations

of 50% above and 50% below the deal price.

Upon review, I find the fair value of SWS as of the merger date to be $6.38

per share.

2
 I. FACTS

The following are the facts as I find them after a four-day trial. I accord the

evidence presented the weight and credibility I find it deserves. Because I do not

find the merger price reliable on the unique facts here, I decline to focus extensively

on the record as it relates to the sales process. In sum, as recited below, I find that

Petitioners’ critiques of the sales process, and Hilltop’s influence on the process, are

generally supported. However, Petitioners’ narrative that SWS was a company on

the verge of a turnaround lacks credible factual support. Instead SWS consistently

underperformed management projections and there is minimal record support that a

turnaround was probable given its structural problems.

A. The Parties and Relevant Non-Parties

There are several Petitioners in this action; each itself an entity. There is no

dispute that the remaining Petitioners’ shares are eligible for appraisal. A collective

7,438,453 SWS common shares held by the Petitioners are at issue in this action.2

The share allocation of each remaining Petitioner is set out below:3

2
Pretrial Order and Stipulation at 5.
3
Id. at 5–6.

3
 Entity Dissenting Shares
Merlin Partners, LP 478,860
AAMAF, LP 429,803
Birchwald Partners, LP 1,425,423
Lone Star Value Investors, LP 1,400,000
Lone Star Value Co-Invest II, LP 2,850,000
Blueblade Capital Opportunities, LLC 696,578
Hay Harbor Capital Partners, LLC 157,789

SWS was a relatively small bank holding company. SWS entered a merger

agreement with Hilltop on March 31, 2014 whereby SWS would merge into a

subsidiary of Hilltop.4 That merger was consummated on January 1, 2015.5

Hilltop itself became a bank holding company following its acquisition of

PlainsCapital in 2012.6 As discussed below, Hilltop, together with Oak Hill Capital

Partners (“Oak Hill”), provided a substantial loan to SWS in 2011 that SWS needed

to maintain proper capital and liquidity levels.7 Pursuant to the terms of the loan

Hilltop’s Chairman, Gerald J. Ford (“Jerry Ford”), was appointed to SWS’s board

in 2011 and remained a SWS director at all relevant times.8 Jerry Ford has

approximately forty years of experience in the bank consolidation business,

4
Id. at 2.
5
Id.
6
See JX049 at 33.
7
See JX015.
8
See id. at 3; JX039 at 77.

4
including certain successful sales.9 Jerry Ford’s son, Jeremy Ford, is the President

and co-CEO of Hilltop.10 In 2011 Jeremy Ford was named as Hilltop’s designated

“observer” on SWS’s board, in connection with the loan, which permitted him to

attend meetings, and review financial and operational reports “to oversee and protect

Hilltop’s investment in SWS.”11

Oak Hill is a Texas based private equity firm which also participated in the

2011 loan to SWS.12 In connection with the loan, Oak Hill was also given a board

seat and an “observer” on SWS’s board.13

B. The SWS Story

1. SWS’s Background

SWS was a Delaware corporation, incorporated in 1972, that traded on the

New York Stock Exchange.14 SWS was a bank holding company with two general

business segments: traditional banking (the “Bank”) and brokerage services (the

“Broker-Dealer”).15 Under the brokerage services umbrella there were certain

general sub-groups including retail brokerage, institutional brokerage, and

9
See JX015 at 3; JX039 at 77.
10
Trial Tr. 327:23–328:2 (Jeremy Ford).
11
Id. at 330:23–331:11 (Jeremy Ford); JX039 at 98.
12
See JX015 at 2.
13
JX008 at 2.
14
JX039 at 7.
15
See id.

5
clearing.16 The banking segment operated eight offices throughout the southwest.17

SWS had significantly more locations and resources dedicated to the brokerage

business.18 In contrast to a traditional bank, SWS had minimal retail deposits—

instead nearly 90% of SWS’s deposits were derived from overnight “sweep”

accounts held by SWS’s Broker-Dealer clients.19 That is, SWS’s banking business

lacked a “stand-alone deposit base.”20 On an employee, asset, and revenue basis the

Bank was smaller than the Broker-Dealer.21 SWS’s CFO explained at trial that his

view of the Company was that “really we were a broker-dealer with a bank

attached.”22

2. SWS Faces Difficulty

SWS had a number of loans, backed by real estate in North Texas, that became

impaired following the Great Recession.23 From 2007 to 2011 the Bank’s non-

performing assets spiked from 2% of total assets to 6.6%.24 Federal regulators

reacted to the impairment of the Bank’s assets. First, in July 2010 the Bank entered

16
See JX043 at 44.
17
See JX039 at 32.
18
See id.
19
Trial Tr. 116:18–117:12 (Miller).
20
Id. at 221:5–6 (Edge).
21
See JX038 at 19; JX759 at SWS_APP002395467.
22
See Trial Tr. 219:11–22 (Edge) (explaining that the banking line of business was acquired in
2000 and that the “roots” of the company were its broker-dealer operations).
23
See id. at 226:3–21 (Edge); JX011 at 12.
24
JX017 at 52.

6
into a Memorandum of Understanding (“MOU”) with federal regulators.25 The

MOU subjected the Bank to additional regulation limiting certain business and

requiring higher capital ratios.26 Second, the MOU was followed by a formal Cease

and Desist order in February 2011, similarly restricting the Bank’s activities and

setting out heightened capital requirements.27

In light of this additional oversight and the need to improve the Bank’s capital

position, SWS began seeking ways to prop up the Bank. Initially, SWS attempted

to transfer capital from the Broker-Dealer to the Bank which included a “fire sale”

of assets, however, this failed to solve the capital issue.28 In fact the transfer from

the Broker-Dealer to the Bank caused the Broker-Dealer business to drop below

threshold capital levels acceptable to counterparties and threatened to impair the

Broker-Dealer business line.29 SWS had preliminary discussions with Hilltop in the

“early fall of 2010 and entered into a non-disclosure agreement with Hilltop,” which

began due diligence review of SWS.30 SWS, however, upon advice of counsel and

advisors elected to pursue a public debt offering.31 In December 2010, SWS

attempted to raise capital through a public offering of convertible unsecured debt,

25
See Trial Tr. 197:14–20 (Chereck).
26
Id. at 226:16–227:6 (Edge).
27
See JX009.
28
Trial Tr. 227:7–21 (Edge).
29
See id. at 252:14–253:15 (Edge).
30
JX011 at 13.
31
Id.

7
which failed due to lack of investor demand.32 Thereafter, SWS returned to the

private market and finalized an arrangement with Oak Hill and Hilltop (the “Credit

Agreement”).

a. The Credit Agreement

The terms of the Credit Agreement were finalized in March 2011,33 and later

approved by stockholders, before the transaction closed on July 29, 2011.34 Pursuant

to the Credit Agreement, Oak Hill and Hilltop made a $100 million senior unsecured

loan to SWS at an interest rate of 8%.35 The Credit Agreement provided that SWS

would issue a warrant to purchase 8,695,652 shares of SWS common stock to both

Oak Hill and Hilltop exercisable at $5.75 a share.36 As a frame of reference, when

SWS pulled its public offering in December 2010, SWS’s trading price dropped to

slightly below $4.00 a share.37 Absent exercise of the warrants, which would

eliminate the debt, or a permissible prepayment the loan would mature in five

32
Trial Tr. 227:22–228:21 (Edge).
33
See JX011 at 7.
34
JX015 at 2.
35
See JX011 at 1.
36
JX011 at 7, 17. The warrants covered the value of each of Oak Hill and Hilltop’s respective
loan principal of $50 million. Id.
37
See Trial Tr. 228:12–17 (Edge).

8
years.38 Upon exercise of the warrants, Oak Hill and Hilltop would own substantial

positions in the Company.39

The same day the Credit Agreement was finalized, SWS entered into an

Investor Rights Agreement with Oak Hill and Hilltop that provided each company

the right to appoint a board member and a board “observer” to SWS’s board.40 The

Credit Agreement itself provided several protections to Oak Hill and Hilltop. This

included, for example, certain anti-takeover clauses which would place the loan in

default if the board ceased to consist of a majority of “Continuing Directors” or if

any other stockholder acquired more than 24.9% of SWS stock.41 Importantly, a

separate portion of the Credit Agreement included a “covenant prohibiting SWS

from undergoing a ‘Fundamental Change’” which was defined to include the sale of

SWS (the “Merger Covenant”).42 Hilltop was not willing to waive the Merger

Covenant during SWS’s sales process.43 However, SWS was permitted to prepay

the loan under certain conditions44—including if the stock price of SWS exceeded

38
See JX011 at 22.
39
When Hilltop’s original ownership of approximately 4% of SWS was combined with its later
exercise of warrants for 8,695,652 shares, it eventually owned 10,171,039 shares or approximately
21% of the company. See JX042 at ix.
40
JX008 at 2. Oak Hill appointed J. Taylor Crandall to the SWS board and selected Scott
Kauffman as its board observer. Id.
41
See JX016 at 38.
42
See JX042 at xii–xiii.
43
See id.
44
See JX016 at 10, 14–15.

9
$8.625 for twenty out of any thirty consecutive trading days.45 That is, if the stock

price reached such a point an acquirer could essentially prepay the loan, and the

Merger Covenant would fall away.

Around the time the Credit Agreement was being negotiated and finalized,

Sterne Agee Group, Inc. (“Sterne Agee”) approached SWS about a potential

acquisition.46 On March 26, 2011, Sterne Agee made an unsolicited conditional

offer to acquire SWS at $6.25 a share, which the board rejected after attempts to

“obtain further information about the offer, including the source of funding and

ability to obtain bank regulatory approval . . . .”47 In rejecting the $6.25 proposal,

the board framed the offer as “highly conditional” and concluded that it

“substantially undervalues the future potential of SWS Group . . . .”48 SWS

implemented defensive measures in response to the offer.49 Stern Agee followed up

with a $7.50 per share cash offer on April 28, 2011.50 SWS rejected that follow-up

offer on May 3, 2011 in favor of the Credit Agreement with Hilltop and Oak Hill.51

In rejecting the offer SWS’s board “unanimously determined that the Sterne Agee

45
See id.; JX042 at xiii.
46
See JX800.
47
Id. at 2.
48
Id. at Ex. 99.2. A corresponding press release by SWS indicated the offer would be reviewed,
and disclosed that previous transaction proposals by Sterne Agee “were not in the best interests of
SWS . . . .” Id. at Ex. 99.1.
49
JX801 at 2–3.
50
See JX014.
51
See JX013.

10
proposal is speculative, illusory, subject to numerous contingencies and

uncertainties, and is clearly not in the best interests of SWS Group Stockholders.”52

The board cited numerous regulatory and financial barriers that Sterne Agee would

face that created serious questions as to “Sterne Agee’s ability to complete a

transaction on a timely basis.”53 Notably, Sterne Agee was not a bank holding

company and would need to secure unlikely regulatory approval to facilitate an

acquisition of SWS’s Bank.54 The SWS board found that the $7.50 bid would

“deprive[] stockholders of the long term value of their shares” pointing out that the

offer was at a substantial discount to SWS’s book value.55 Testimony at trial

clarified that Sterne Agee was an unlikely acquirer and never made an “actionable”

offer.56

b. SWS after the Credit Agreement

Following the Credit Agreement, and the regulatory interventions SWS

implemented a plan to turn the business around. The success of the “turnaround”

was the subject of substantial litigation effort.

From 2011 through 2014 SWS management prepared annual budgets. The

budgets were formulated by going to individual business sector heads, collecting

52
Id. at 1–2.
53
Id. at 2.
54
Id. See also Trial Tr. 10:18–12:6 (Sterling).
55
JX013 at 2.
56
Trial Tr. 10:18–12:6 (Sterling).

11
their projections, and then aggregating them.57 Frequently, management would ask

the business heads for more “aspirational” goals or projections to get numbers they

were comfortable taking to the full board.58 Single year projections were then

extrapolated out into three year “strategic plans” which assumed each individual

year’s budget would be met.59 SWS, however, never met its budget between 2011

and 2014.60 In that vein, management forecasts anticipated straight-line growth in

revenue and profits, but SWS failed to hit the targets and continued to lose money

on declining revenues.61

Robert Chereck became CEO of SWS in 2012, after being recruited by Jerry

Ford.62 Chereck helped to implement changes at the Bank which ultimately led to

the termination of the Cease and Desist order in 2013, presumably because the Bank

had reached adequate capital levels and returned to prudent lending.63 SWS was

able to reduce its volume of problem loans,64 but the Bank, overall, produced “very

disappointing results.”65 The Broker-Dealer business line essentially remained

stagnant.66 SWS was accruing “a deferred tax asset” in the form of a net operating

57
Id. at 256:4–257:2 (Edge).
58
Id.
59
Id. at 257:8–258:7 (Edge).
60
Id. at 258:8–10 (Edge).
61
See, e.g., JX028 at F-3; JX020 at F-3.
62
Trial Tr. 196:7–23 (Chereck).
63
See id. at 210:7–211:10 (Chereck).
64
See, e.g., JX043 at 47; JX017 at 35.
65
Trial Tr. 106:23–107:11 (Miller).
66
See JX028 at F-46.

12
loss.67 In June 2013, the Company made an accounting decision to write down, in

the form of a valuation allowance, approximately $30 million of its net operating

losses, because after several years of losses in a row, the Company did not believe it

would be able to generate “enough income in the future to use up that operating loss

in the requisite time frame.”68 This decision was made in the context of an audited

accounting determination. I find that the decision—to provide for a valuation

allowance because it was more likely than not that such losses could not be offset by

income during the requisite period69—implies that managements’ straight-line

growth and profitability projections were optimistic.70

The Respondents identify two “structural impediments” to growth which they

assert were demonstrated by the trial record.71 First, the Respondents point to trial

testimony regarding SWS’s size. For example, Tyree Miller of SWS’s board,

testified that SWS “was subscale in every area” and such lack of scale impeded

growth.72 Both regulatory requirements,73 and technology and back office costs,74

67
See Trial Tr. 237:2–21 (Edge); JX028 at 24.
68
Trial Tr. 237:2–21 (Edge).
69
See id. at 237:2–238:2 (Edge).
70
See id. I note that the company appears to have kept the tax deferred assets on the books, but
placed a $30 million valuation allowance against it. See id.; JX028 at 24. See also JX503 at
SWS_APP00094172–73.
71
Respondents’ Post-Trial Opening Br. 11.
72
Trial Tr. 108:23–24 (Miller); id. at 106:23–107:11 (Miller).
73
See id. at 198:15–22 (Chereck).
74
See id. at 300:3–302:14 (Roth). For example, compliance, online banking, and cyber security
costs were spread over a much smaller number of clients than at larger banks. See id.

13
burdened the Bank at its scale, as it had a smaller base to spread those costs across.

Second, the Respondents point to testimony that SWS was a “people business,” and

that its best assets were its people.75 This was particularly true of the Broker-Dealer

business and SWS’s scale problems along with its publicized regulatory and capital

problems made it difficult to retain client advisors. From 2009 to 2012 the Broker-

Dealer lost approximately one third of its client advisors.76 The Bank business at

SWS also struggled to retain and recruit loan officers in light of SWS’s well-

publicized woes.77 The Petitioners narrative is that following termination of the

Cease and Desist order and the changes implemented prompting the termination,

SWS was on the brink of a turnaround. All parties agree that certain improvements

were made to SWS’s problem assets78 and balance sheet. I find that the Company’s

recent history and the record at trial supports the Respondents’ witnesses testimony

that the Company would continue to face an uphill climb to compete at its size going

forward.79

By August 2013, the board was becoming frustrated by the Company’s

performance and directed SWS’s CEO to take action—specifically to cut costs by

75
Id. at 232:6–233:8 (Edge).
76
Id. at 232:20–233:15 (Edge).
77
Id. at 201:18–203:8 (Edge).
78
See, e.g., JX820.
79
See, e.g., Trial Tr. 36:6–7 (Sterling) (describing the company as “a melting ice cube for many
years . . .”). See also id. at 244:5–10 (Edge).

14
10% within thirty days.80 The purpose of these cuts was not to stimulate growth, but

rather to bring down the expense base in “an attempt to get margins up.”81 By the

end of the year, nearly all of the cuts had been implemented. The savings expected

were upwards of $18 million82—which included eliminating over 100 jobs,

including thirty-two revenue-producing employees.83 Around this time federal bank

regulators were conducting their annual review, which for the most part noted that

SWS’s condition had improved, however, they raised a concern about SWS’s ability

to repay the $100 million note.84 The board remained concerned about the

Company’s condition and the ability of SWS to pay off its loan to Hilltop, and return

to profitability and growth.85

3. The Sales Process

Prior to SWS launching a sales process there was noise by analysts in the

market that SWS was an acquisition target,86 and that Hilltop, since it had recently

become a bank holding company via its acquisition of PlainsCapital, was a likely fit

for a synergies-driven transaction.87 SWS stock traded higher upon this speculation.

80
See id. at 244:14–245:1 (Edge).
81
Id. at 109:12–17 (Miller).
82
See JX089 at SWS_APP00002583.
83
See JX102 at SWS_APP00235079–82.
84
See Trial Tr. 248:4–15 (Edge).
85
See id. at 107:24–109:2 (Miller).
86
See, e.g., JX049 at 33.
87
Id. See Trial Tr. 429:16–432:10 (Eberwein). CEO of Petitioner Lone Star, Jeff Eberwein,
invested on this thesis accumulating a position in SWS. See, e.g., id.; id. at 433:20–437:22
(Eberwein).

15
The analysts were correct—prior to SWS launching a sales process Hilltop was

actively considering a purchase of SWS—and by October 2013 Jeremy Ford,

Hilltop’s board observer, had drafted an analysis to present to Hilltop’s directors in

support of an SWS acquisition.88 SWS was not aware of Hilltop’s interest at this

time, however.89 In preparing his analysis Jeremy Ford had access to information

via his position as a board observer that others in the market would not have had

access to, including, for example, loan tapes,90 SWS board meeting materials,91 and

access to SWS management. At no time did Jeremy Ford inform SWS of Hilltop’s

interest, that it was analyzing SWS as a target, or that Hilltop was considering a

tender offer.92 Hilltop’s internal projections reveal that following integration of

PlainsCapital, an SWS acquisition would derive much of its benefits from cost-

savings in reduction of overhead rather than SWS’s stand-alone performance.93

Thus, Hilltop’s acquisition thesis was synergies-driven.94

On January 9, 2014, Hilltop made an offer to acquire SWS for $7.00 per share,

payable in 50% cash and 50% Hilltop stock.95 SWS’s trading price on January 9,

88
Id. at 365:14–366:2 (Jeremy Ford).
89
See id.
90
See, e.g., JX090; JX095.
91
See, e.g., JX089; JX091.
92
Trial Tr. 387:1–388:7 (Jeremy Ford).
93
See, e.g., JX906 at HTH00020915–17.
94
See id. at HTH00020921; Trial Tr. 340:4–341:11 (Jeremy Ford). See also JX002 at Ex. 15
(calculating Hilltop’s expected savings per share).
95
JX153.

16
2014—with some merger speculation in the market but prior to the announcement

of the offer—was $6.06, and the one-year average of SWS in the previous year was

$5.92. SWS responded by creating a Special Committee to consider the offer on

January 15, 2014.96 The Special Committee “knew there were very, very strong

synergy values already partly reflected . . .” in the initial offer but wanted to

“convince Hilltop” to share more of the synergies with SWS shareholders.97

The process the Special Committee ran, and whether it was independent or

“straightjacketed,” was also the subject of substantial litigation effort. As I do not

rely on the deal price, I need only briefly address the matter here. The Committee

was represented by legal and financial advisors.98 The financial advisor retained by

the Special Committee asked management to update its most recent three year

projections, which at the time ended in June 2016, to run through the end of calendar

year 2017.99 While management dialed back some of the growth assumptions, due

to the failure to meet prior-period projections,100 management projections were still

“optimistic” and projected growth and “net additions to the business.”101 That is, the

96
See JX177.
97
Trial Tr. 114:15–115:10 (Miller).
98
JX187. I note, however, the Petitioners attack the selection of the financial advisor and suggest
that the advisor was conflicted. See, e.g., Petitioners’ Post-Trial Opening Br. 9–10.
99
See Trial Tr. 15:6–16:14 (Sterling).
100
See id. at 258:11–259:9 (Edge).
101
Id. at 259:10–20 (Edge).

17
revised management projections still relied on a number of favorable assumptions.102

A visual representation of those projections are set out in Figure 1 below.

Figure 1103

Following Hilltop’s bid, the Special Committee’s financial advisor contacted

seventeen potential merger partners for SWS in early February 2014.104 Besides

Hilltop, two other entities expressed interest, as discussed below.

a. Esposito

Esposito is a small Dallas, Texas broker-dealer.105 Esposito had

approximately $10 million in capital.106 Esposito made an expression of interest in

102
See id. at 20:6–15 (Sterling); id. at 205:9–16 (Chereck); id. at 116:3–13 (Miller).
103
This demonstrative is for ease of explanation and condenses a number of factual sources from
the record. It can be found in the Respondents’ expert report. See JX002 at 8.
104
JX042 at 240.
105
See Trial Tr. 118:6–119:2 (Miller).
106
Id.

18
SWS at $8.00 per share on February 12, 2014, subject to a slew of conditions,

including securing financing.107 Shortly thereafter Esposito released a press release

publicizing its $8.00 expression of interest.108 Esposito was unknown to the entire

Special Committee despite their decades of experience in the area.109 Nonetheless

the Special Committee engaged with Esposito to try to obtain additional information

regarding its plans to finance the transaction and secure regulatory approval.110 This

revealed that Esposito would need the assistance of another small regional bank—

Triumph Bancorp, who together with Esposito, would seek out $300 million from

three private equity firms to finance the deal.111 Certain communications indicate

that SWS “stiff-armed” Esposito.112 Stiff-armed, or otherwise, Esposito was not able

to pull together the requisite financing and secure a path towards regulatory

approval; thus, neither Esposito nor Triumph made a formal offer.113

107
JX222. I note this indication of interest appears to have been made, at least in part, at the
suggestion of the CEO of one of the Petitioners here—Lone Star. See JX212; JX195.
108
JX236.
109
Trial Tr. 118:6–16 (Miller).
110
See JX261; Trial Tr. 118:10–119:24 (Miller).
111
See Trial Tr. 118:10–119:24 (Miller); JX292. As of March 15, 2014 Triumph’s CEO still had
“no idea whether this deal makes sense at $8.00 per share (or any price for that matter).” JX335.
112
JX232. Specifically, the Special Committee’s financial advisor indicated on February 14, 2014
that he was going “to stiff arm [Esposito] shortly.” Id. Esposito also felt “stiff-armed.” See JX212
(indicating that Esposito received “a clear stiff arm” from the financial advisor).
113
See Trial Tr. 120:1–3 (Miller).

19
 b. Stifel

In February 2014, Stifel emerged as a second interested acquirer. The parties

heavily dispute whether Stifel was truly interested and capable of consummating a

transaction with SWS. The Petitioners argue that Stifel was improperly shut out of

the sales process despite having the means and the interest to submit a topping bid

to Hilltop’s proposal. The Respondents’ narrative is that Stifel had a “reputation”

and “history” of pursuing sales processes, backing out, and poaching key

employees.114 Nonetheless the Special Committee instructed its financial advisor to

solicit interest from Stifel,115 and Stifel expressed interest at $8.15 a share. The

Respondents assert that Stifel was then “difficult” in carrying out due-diligence,

arguing that Stifel insisted on “unusually personalized diligence.”116 SWS and Stifel

engaged in robust negotiation over a non-disclosure agreement (“NDA”).117 The

process of consummating a NDA was protracted; Stifel finally signed it on March

18, 2014.118 The Special Committee, apparently dragging its feet, did not

countersign the NDA immediately,119 and by March 21, Stifel had withdrawn its

signature.120

114
See, e.g., id. at 38:16–40:11 (Sterling).
115
Id. at 38:4–7 (Sterling).
116
Respondents’ Post-Trial Opening Br. 25.
117
See, e.g., Trial Tr. 121:18–122:16 (Miller).
118
JX355; Trial Tr. 70:8–10 (Sterling).
119
See e.g., JX368; Trial Tr. 74:15–79:16 (Sterling).
120
See JX380.

20
 As discussed below, an initial handshake deal was reached between Hilltop

and SWS on approximately March 20, 2014. Stifel, unaware of this, continued its

expression of interest, at a price above Hilltop’s offer.121 This information was taken

to the Special Committee at a March 24, 2014 meeting, which initially favored

signing a NDA.122 However, when this information was relayed to Jerry Ford he

“blew his top,” and demanded that the deal be signed with Hilltop by March 31,

2014 or he was withdrawing his offer and resigning from the board.123 Further Jerry

Ford indicated that Hilltop would not waive the Merger Covenant.124 A NDA was

eventually executed with Stifel, and by March 27, 2014 Stifel made a proposal at

$8.65 a share.125 According to Stifel’s March 27 letter to SWS, the proposal was

non-binding and subject to due diligence, and Stifel stated that it believed its

proposal “would not be subject to blocking” by the Merger Covenant.126 Stifel

proposed to finish diligence by March 31,127 and internal Stifel documents

demonstrate that its price was driven significantly by synergies.128 Stifel’s access to

SWS’s building and the diligence data room in the days leading up to the March 31

121
Trial Tr. 79:17–21 (Sterling).
122
JX388 at 2.
123
See Trial Tr. 80:11–81:4 (Sterling); JX388 at 2.
124
See id.
125
See Trial Tr. 81:9–82:5 (Sterling).
126
JX421.
127
See JX426.
128
See JX482 at STIFEL0000082 (indicating Stifel expected to save or cut costs by approximately
35%).

21
deadline is in dispute. The same is true for whether SWS and the committee were

adequately cooperating with Stifel, and whether Stifel’s interest at its announced

price-point was genuine. Shortly before the deadline the Special Committee asked

Stifel if it would raise its offer to $9.00 per share.129 Stifel was not able to complete

its diligence to its satisfaction and asked for an extension via letter of March 31,

2014.130 The extension request also suggested that the Merger Covenant now

presented a problem for Stifel.131 No extension was granted.

c. Hilltop and the Committee Recommendation

Hilltop’s initial $7.00 per share offer was rejected by the committee as

“inadequate” and “undervalued” SWS per the Special Committee’s meeting

minutes.132 As mentioned above, however, at trial members of the Special

Committee testified to their belief that the initial offer significantly shared synergies,

and that going forward the object of bargaining would be to extract additional

synergy value for SWS shareholders.133 On March 19, 2014 Hilltop raised its offer

to $7.50 a share with a ratio of 25% cash and 75% Hilltop stock.134 The Special

Committee countered at $8.00.135 On March 20, while Stifel’s NDA was still

129
Trial Tr. 163:14–22 (Miller); JX486.
130
See JX509.
131
See id.
132
JX269.
133
See Trial Tr. 114:15–115:10 (Miller).
134
JX367.
135
Trial Tr. 343:1–344:17 (Jeremy Ford).

22
pending the Special Committee met and instructed the financial advisor to ask

Hilltop to increase its offer to $7.75.136 Hilltop believed it had a “handshake” deal

at $7.75.137 As discussed above Hilltop become upset at the prospect of another

bidder entering the picture, which it viewed as a “retrade” or suspected negotiation

tactic, and made clear that $7.75 was best and final.138 Thus, Hilltop set the March

31, 2014 deadline to accept or reject its offer.139

The Special Committee met on March 31, 2014 to consider Hilltop’s offer and

review the sales process.140 The Committee’s financial advisor provided a fairness

opinion which opined the proposed transaction was fair to SWS’s stockholders.141

The financial advisor did, however, recognize that the Company informed it that the

Credit Agreement may place “significant constraints on the Company’s ability to

sell itself . . . .”142 As of the self-imposed March 31 deadline Hilltop was the only

acquirer that had made a firm offer.143 The Committee viewed the offer as “a very

solid offer” that they knew could actually close and determined that accepting it was

the appropriate course of action in light of the Company’s “precarious financial

136
See id. at 76:12–78:10 (Sterling).
137
Id. at 343:1–344:10 (Jeremy Ford).
138
Id. at 343:20–344:17 (Jeremy Ford).
139
See id.
140
JX516.
141
See id.; JX500.
142
JX530 at SANDLER00014168.
143
See Trial Tr. 140:21–141:21 (Miller).

23
position.”144 Further, in light of the financial advisor’s opinion that the offer was

fair, the committee recommended it to the full board.145 The SWS board approved

the merger later that day on the terms described above: $7.75 a share with 75%

Hilltop stock and 25% cash.146

4. Post-Deal Developments

Shortly after the deal was announced, certain Petitioners started accumulating

shares for appraisal investment funds. The world of appraisal arbitrage does not lack

for irony: Included in these Petitioners’ solicitations of investments was the

disclosure that a prime investment risk to their business strategy of dissent from the

merger was that a majority of stockholders would do the same. 147 In that case, the

deal would not close and they would remain investors in SWS as a going concern.148

Prior to the record date for the merger, Oak Hill exercised the majority of its warrants

on September 26, 2014, acquiring 6.5 million SWS shares thereby eliminating $37.5

million in debt.149 On October 2, 2014, Hilltop exercised its warrants in full and

received approximately 8.7 million SWS shares, and as a result $50 million in SWS

debt was eliminated.150 A proxy advisory service noted that SWS’s viability as a

144
See id.; JX516.
145
See Trial Tr. 140:21–141:21 (Miller); JX516.
146
See JX524.
147
See, e.g, JX600 at LSV0002117, LSV0002121.
148
See id. This same investment group also threatened a proxy contest in 2014 to replace certain
directors. See JX616.
149
JX656.
150
JX670.

24
stand-alone entity was harmed by both market conditions and its poor performance

over the past five years.151 However, this same proxy advisor, although it supported

the merger, also indicated that the “merger consideration is clearly not the optimal

outcome of the 2014 sales process, but it may, cumulatively, be an acceptable

outcome when considering the entire 2011-2014 process.”152 SWS continued to

struggle to turn a profit. Financial results for fiscal year 2014, released on September

26, 2014 revealed a decline in net revenue from $271 million to $266 million.153

While some sectors of SWS’s business improved, management forecasts were not

met and SWS recorded a net loss of $15.6 million.154 The merger was approved by

a special stockholder meeting on November 21, 2014 and closed on January 1, 2015.

In the several months between the announcement of the merger agreement and the

stockholder vote, no other bidder emerged. Due to fluctuation in Hilltop’s stock, the

value of the merger consideration had decreased to $6.92 per share.

C. The Experts

As is typical in these proceedings, the experts present vastly divergent

valuations. In sum, neither expert attempts to invoke the deal price in light of the

unique relationship between the buyer and seller and the sales process outlined

151
See JX705 at SWS_APP00193843.
152
Id. at SWS_APP00193835.
153
JX039 at 36.
154
JX759 at SWS_APP00239432–33.

25
above. The Petitioners’ expert, David Clarke, is a well-seasoned valuation expert

with over thirty-five years of providing valuation opinions and expert testimony in

various types of valuation litigation.155 Clarke employed a valuation which places

80% weight on his DCF analysis and 20% on a comparable companies analysis.

Clarke arrives at a fair value of $9.61 per share, for a total value of SWS of $483.4

million.156 The Petitioners offer several purported explanations for the divergence

from the deal price, including flaws in the sales process, and the failure to account

for SWS being on the verge of a turnaround. The Respondents’ expert, Richard

Ruback, a Corporate Finance Professor with substantial experience in expert

testimony, places 100% weight on his DCF analysis.157 His analysis results in a

$5.17 per share valuation. The Respondents’ explanation for its expert’s valuation

falling below the merger price is that certain “shared synergies” are included in the

merger price, but not properly considered fair value in an appraisal action. The

experts’ positions are discussed in more detail in the analysis portion of this

Memorandum Opinion.

155
See JX001 at Appendix B.
156
See id. at 53; JX004 at 34 (correcting initial per share valuation for the proper number of shares
outstanding).
157
See JX002 at 27, 29, 38–40.

26
 D. Procedural History

Several separate appraisal petitions were initially filed in January 2015, and

the petitions were later consolidated. A four-day trial was held in September 2016,

followed by extensive post-trial briefing. After the conclusion of post-trial briefing,

closing argument was held on December 14, 2016. At the conclusion of closing

argument I requested that the parties submit essentially a stipulated list of issues

arising from the evidence of value.158 That exercise proved helpful in highlighting

the differences between the parties. However, it failed to result in a stipulated list of

issues, and led to further motion practice.159 What follows is my decision on the fair

value of SWS.

II. ANALYSIS

This is a statutory proceeding pursuant to 8 Del. C. § 262 (the “Appraisal

Statute”). Once the procedural strictures are met and entitlement to appraisal is

perfected, the Appraisal Statute provides shareholders who did not vote in favor of

certain transactions a statutory right to have this Court value their shares.160 The

only issue before me here is the value of the Petitioners’ shares.

The Appraisal Statute provides that “the Court shall determine the fair value

of the shares exclusive of any element of value arising from the accomplishment or

158
See Dec. 14, 2016 Oral Argument Tr. 122, 124.
159
See Dkt. No. 222.
160
See 8 Del. C. § 262.

27
expectation of the merger . . . .”161 Unlike traditional adversarial legal proceedings,

the burden of proof is not specifically allocated to a party—rather the Court, via

statute, has the duty to determine the fair value of the shares.162 Therefore,

“[u]ltimately, both parties bear the burden of establishing fair value by a

preponderance of the evidence.”163 The corporation is to be valued as a going

concern,164 taking “into account all relevant factors,”165 including the “‘operative

reality’ of the company as of the time of the merger.”166 That is, the fair value

calculation focuses on “the value of the company as a going concern, rather than its

value to a third party as an acquisition.”167

Despite the burden of articulating fair value ultimately falling on the Court, I

am, as a practical matter, generally guided in my valuation by the adversarial

presentations of the parties. After evaluating those presentations and the trial record,

the Court may “select one of the parties' valuation models as its general framework,

or fashion its own, to determine fair value in [an] appraisal proceeding.”168 The

161
8 Del. C. § 262(h) (emphasis added).
162
See, e.g., Laidler v. Hesco Bastion Envtl., 2014 WL 1877536, at *6 (Del. Ch. May 12, 2014)
(explaining that “[i]n an appraisal proceeding, the burden to establish fair value by a preponderance
of the evidence rests on both the petitioner and the respondent”) (citation omitted).
163
Merion Capital LP v. BMC Software, Inc., 2015 WL 6164771, at *11 (Del. Ch. Oct. 21, 2015).
164
See M.G. Bancorporation, Inc. v. Le Beau, 737 A.2d 513, 525 (Del. 1999) (citation omitted).
165
8 Del. C. § 262(h).
166
Le Beau, 737 A.2d at 525 (citation omitted).
167
In Re Appraisal of Petsmart, Inc., 2017 WL 2303599, at *27 (quoting M.P.M. Enters., Inc. v.
Gilbert, 731 A.2d 790, 795 (Del. 1999)).
168
Cede & Co. v. Technicolor, Inc., 684 A.2d 289, 299 (Del. 1996) (citation omitted).

28
Court has “significant discretion to use the valuation methods it deems appropriate .

. . .”169 That is, “appraisal is, by design, a flexible process” and “vests the [Court]

with significant discretion to consider ‘all relevant factors' and determine the going

concern value of the underlying company.”170

A. The Appropriate Valuation Methodology Here

A line of decisions in this Court have invoked the merger price as the best

indication of fair value.171 Certain common threads run through these decisions

making the merger price, in those circumstances, the best indicator available—

including a sales process which exposed the company sufficiently to the market such

that if the market valued the asset at a higher price, it is likely that a bidder would

have emerged.172 Similarly, cases invoking the merger price generally involve a

relatively clean sales process. However, when the merger price represents a transfer

to the sellers of value arising solely from a merger, these additions to deal price are

properly removed from the calculation of fair value.173

169
See In re Appraisal of DFC Glob. Corp., 2016 WL 3753123, at *5 (Del. Ch. July 8, 2016)
(citation omitted).
170
Golden Telecom, Inc. v. Glob. GT LP, 11 A.3d 214, 217–18 (Del. 2010).
171
See Merion Capital L.P. v. Lender Processing Servs., Inc , 2016 WL 7324170, at *30–31 (Del.
Ch. Dec. 16, 2016) (collecting recent cases relying on the deal price).
172
See, e.g., LongPath Capital, LLC v. Ramtron Int'l Corp., 2015 WL 4540443, at *24 (Del. Ch.
June 30, 2015) (relying on the deal price and concluding that “[t]his lengthy, publicized [sales]
process was thorough and gives me confidence that, if Ramtron could have commanded a higher
value, it would have”). See also In Re Appraisal of Petsmart, Inc., 2017 WL 2303599, at *2
(adopting the deal price where “the evidence does not reveal any confounding factors that would
have caused the massive market failure, to the tune of $4.5 billion . . .”).
173
Ramtron Int'l Corp., 2015 WL 4540443, at *25–26 (relying on the deal price and excluding
proven synergies arising from the specific transaction).

29
 In this case, in light of the facts recounted in the background section of this

Memorandum Opinion, certain structural limitations unique to SWS make the

application of the merger price not the most reliable indicia of fair value. Neither

party relied on deal price to demonstrate fair value. Here, because of the problematic

process, including the probable effect on deal price of the existence of the Credit

Agreement under which the acquirer exercised a partial veto power over competing

offers, I find it inappropriate to rely on deal price and instead perform my statutory

duty by employing traditional valuation methodologies.

The parties have presented two valuation methodologies: a comparable

companies valuation by the Petitioners, and dueling DCF analyses by both the

Petitioners and the Respondents. The selection of valuation methodologies is fact

specific and necessarily dependent on the support in the trial record. A comparable

companies analysis is appropriate only where the companies selected are truly

comparable.174 The burden of establishing that companies used in the analysis are

actually comparable rests upon the party seeking to employ the comparables

method.175 The selected companies need not be a perfect match; however, to be

useful the methodology must employ “a good sample of actual comparables.”176

174
See, e.g., Laidler, 2014 WL 1877536, at *8 (rejecting a comparable companies analysis where
the proponent failed to demonstrate the companies were “truly comparable”).
175
See ONTI, Inc. v. Integra Bank, 751 A.2d 904, 916 (Del. Ch. 1999) (“The burden of proof on
the question whether the comparables are truly comparable lies with the party making that
assertion . . . .”).
176
In re Orchard Enterprises, Inc., 2012 WL 2923305, at *10 (Del. Ch. July 18, 2012).

30
 Here the companies selected by Clarke in his comparable company analysis

diverge in significant ways from SWS in terms of size, business lines, and

performance. The record reflects that SWS, because of its unique structure, size and

business model had few, if any, peers. Thus, finding comparables is difficult. Clarke

compounded this challenge by selecting companies in both the Banking and Broker-

Dealer lines of business that were dissimilar in size to SWS,177 some of which also

had other characteristics making them not truly comparable.178 On the facts of this

case, I do not find Clarke’s comparable-companies analysis sufficiently supported

by the record to be reliable; thus, I employ the DCF methodology exclusively here.

B. The Court’s DCF

Below I review the experts’ positions on contested inputs to the DCF

valuation, and then decide the appropriate value of each input in light of the record

established at trial and the law of this State. The DCF valuation, although complex

in practice, is rooted around a simple principle: the value of the company at the time

of the merger is simply the sum of its future cash flows discounted back to present

value. The calculation, however, is only as reliable as the inputs relied upon and the

177
See JX005 Exs. 9.2, 10.
178
See, e.g., id. at 21–22 (explaining that a banking comparable used by Clarke, Green Bancorp,
was a new public company pursuing a high growth rate via strategic acquisitions); id. at 20–21
(explaining how other comparables had undergone mergers during the relevant time).

31
assumptions underlying those inputs. Below, I select the inputs I find best supported

by the factual record.

1. The Appropriate Cash Flow Projections

This Court has long expressed its strong preference for management

projections. Naturally, prior appraisal decisions have recognized that it is proper to

be skeptical of “post hoc, litigation-driven forecasts” by experts.179 Similarly, the

cash flow projections have been described by this Court as the “most important

input” in performing a DCF, and that absent reliable projections “a DCF analysis is

simply a guess.”180 Reliable management projections of cash flows in advance of

the merger are favored over litigation-facing expert derived projections.181

As described earlier, management routinely prepared three-year projections

which, in connection with the sales process, management extended at the request of

the Company’s financial advisor to run through December 2017.182 All parties rely

on these projections,183 with reservations. The Petitioners refer to the management

projections as “Downside” projections because they had been adjusted downward

179
See Owen v. Cannon, 2015 WL 3819204, at *21–22 (Del. Ch. June 17, 2015).
180
Delaware Open MRI Radiology Assocs., P.A. v. Kessler, 898 A.2d 290, 332 (Del. Ch. 2006).
With reliable inputs, a DCF valuation may be considered an educated guess.
181
See id. See also Cede & Co. v. JRC Acquisition Corp., 2004 WL 286963, at *2 (Del. Ch. Feb.
10, 2004) (providing that this “Court prefers valuations based on management projections
available as of the date of the merger and holds a healthy skepticism for post-merger adjustments
to management projections or the creation of new projections entirely”).
182
See supra notes 99–103 and accompanying text.
183
See Petitioners’ Post-Trial Opening Br. 41 (stating “both experts relied on Management
Projections”).

32
from previous projections.184 The Respondents characterize the projections as

overly optimistic, as SWS’s actual performance “never came close to Management

Projections.”185 The Respondents’ expert, Ruback, takes the management

projections as they are, without adjustment.186 The Petitioners’ expert, Clarke, made

several major adjustments to the management’s projections of cash flows. Clarke

also chose to extend the projections by two years.187

As do the parties, I adopt the management projections as my starting point. I

review each proposed alteration in light of the record.

a. The 2018 and 2019 Extension

The first major alteration advanced by the Petitioners is Clarke’s extension of

management projections for two additional years. The Petitioners frame this issue

as whether SWS reached a “steady state” by the end of the management projections.

They assert that a second-stage period of two years, covering calendar years 2018

and 2019, is necessary to “normalize SWS’s financial performance before

calculating a terminal value.”188 The Petitioners’ primary contention is that as a

matter of valuation methodology the Company had not reached a “steady state” by

the end of management projections, thus it is necessary to extend the projection until

184
Id. at 39.
185
Respondents’ Post-Trial Answering Br. 23.
186
See Dkt. No. 221, Ex. at 1.
187
See Petitioners’ Post-Trial Opening Br. 41.
188
Dkt. No. 230 at 2 (Petitioners’ List of DCF Disputes).

33
they reached such a state before performing the terminal value calculation.189 The

basis for the Petitioners’ conclusion that a steady state was not reached is that SWS’s

profit margin at the end of management projections “was well below projected

comparable company margins . . .” and that ROAA (return on average assets) was

not in line with peers.190

There are a number of subsidiary assumptions necessary to allow the

Petitioners’ premises to stand, and the extensions to be factually supported. Those

include that the so-called peer firms are actually comparable,191 and that SWS, in

light of its scale problems, could ever have performance similar to or greater than

larger entities.192 Further, adopting Clarke’s specific projection extensions would

require me to find that SWS would continue an additional two years of

unprecedented straight-line growth, reaching a profit margin far exceeding any

management projections, despite the Company’s structural issues and performance

189
Petitioners’ Post-Trial Opening Br. 41–42.
190
See id. at 42, 48–49.
191
Most of the “comparables” were significantly larger—and therefore less likely to face SWS’s
persistent scale problems. See, e.g., JX005 at Ex. 10.
192
For example, the Petitioners argue ROAA needed to reach 1% before a steady state was reached.
See Petitioners’ Post-Trial Opening Br. 48–49. However, SWS had averaged a ROAA of 0.22%
since the year 2000. See JX005 at Ex. 2. Further, the Broker-Dealer operation provided lower
ROAA than the Bank, thus the Bank would have to significantly exceed 1% ROAA in order for
SWS to have an overall ROAA of 1%. See Trial Tr. 223:6–224:12 (Edge); Trial Tr. 670:12–23
(Clarke).

34
problems.193 I note that the Respondents’ expert concluded that SWS had reached a

steady state, and did so based on SWS’s ability to perform against similar firms. 194

I find the premises underlying the rationale for the extension unsupported,195

and that Clarke’s post hoc extensions to management’s projections are not proper

here. On the eve of the merger SWS was continuing to lose money on declining

revenues.196 Similarly, the record, on balance, supports a finding that at the end of

three years the Company would reach a steady state.197 On the record before me,

there is inadequate evidence to support the extension of straight-line unprecedented

growth and I employ the three-year management projections as the starting point.198

Ruback’s DCF model uses management’s three year projections, as I have

found supported here. Therefore, I begin with Ruback’s general model subject to

193
See, e.g., Trial Tr. 264:2–13 (Edge).
194
See JX005 at 5–6.
195
See Trial Tr. 264:2–13 (Edge) (testifying that management would not have signed off on
Clarke’s extensions as the profit margin Clarke argued SWS needed to reach a steady state “would
not be reasonable”).
196
See, e.g., JX036 at 36.
197
See JX005 at 6. See also Trial Tr. 261:8–12 (Edge) (“And then we thought it was appropriate
to have obviously one full year of kind of steady state, stand-alone, didn’t have the noise of the
transaction or anything. And that’s how we settled it going through the end of 2017.”).
198
See also Trial Tr. 708:1–710:5 (Ruback) (testifying that the appropriate measure for a steady
state here is when SWS was “as good relative to [its] peers as [it] c[ould] be”). Ruback concluded
that 2017 was a reasonable time at which to stop the projections as SWS’s turnaround would have
slowed or been complete. See id. at 713:19–22 (Ruback). I find that conclusion reasonable on the
facts here. See also id. at 15:18–16:4 (Sterling) (explaining that management thought extending
projections beyond 2017 presented “too much uncertainty”).

35
the adjustments set out below.199 That is, management’s projections of net income

for calendar years 2015 through 2017 of $37,075,000, $35,465,000 and $28,283,000,

respectively serve as the starting point for my calculation.200

b. The 2014 warrant exercise and SWS’s Capital Level

The next major adjustment advocated by the Petitioners intertwines two

issues: should the warrant exercise be considered in valuing SWS, 201 and what, if

any, excess regulatory capital SWS held should be distributed in the valuation

model. That is, if the warrant exercise is considered part of the Company’s operative

reality as of the merger date, in the Petitioners’ view the Company will have less

debt and thus greater excess regulatory capital. The parties present me with binary

and divergent positions. They differ as to whether the warrant exercise should be

part of the operative reality of the company as of the merger date. Partly as a result,

the Respondents and the Petitioners advocate that fair value should include $0 and

$117.5 million, respectively, as the amount of excess regulatory capital distributable.

I consider their positions, below.

199
That is, my calculations below are made using the described adjustments to Ruback’s model
supplied to the Court. That framework is located in Ruback’s Expert Report. See JX002 at Exs.
6, 7.
200
See JX001 at 25; JX002 at 8.
201
Neither party disputes that the warrant exercise caused an increase in regulatory capital; the
Respondents argue, however that this increase should not be considered here, because it arose from
the merger, and it introduced no additional cash to SWS but instead simply canceled SWS debt.
See Respondents’ Post-Trial Opening Br. 60 n.245.

36
 i. The Warrant Exercise was Part of SWS’s Operative
Reality

In an appraisal proceeding the Court is to exclude speculative elements of

value that arise from the “accomplishment or expectation” of a merger.202 However,

the “accomplishment or expectation” of the merger exception is “narrow” and is

designed to eliminate speculative projections relating to the completion of a

merger.203 Further, the “narrow exclusion does not encompass known elements of

value, including those which exist on the date of the merger . . . .”204 Here, it is

undisputed that the warrant exercises were known well in advance of the merger

closing: in fact, the record indicates that the warrants were exercised to enable the

holders “to vote for the merger.”205 The shares issued in the warrant exercise,

totaling approximately 15,217,391, were all voted in favor of the merger. The

Respondents argue the warrant exercise should be excluded and the changes it

worked to SWS’s capital structure should not be considered.206 They essentially

advance a “but for” test; but for the merger these warrants would not have been

exercised when they were, and therefore they are an element of value arising solely

202
8 Del C. § 262(h); Weinberger v. UOP, Inc., 457 A.2d 701, 713 (Del. 1983).
203
See Cede & Co. v. Technicolor, Inc., 684 A.2d 289, 299 (Del. 1996).
204
Id. (emphasis added) (citation omitted).
205
See Respondents’ Post-Trial Opening Br. 66. Similarly, and unlike the facts in certain cases
relied on by the Respondent, here the warrant exercise was not conditioned in any way on the
merger: here those exercising the warrants simply made the independent decision to exercise in-
the-money warrants before the record date to vote for the merger.
206
See Respondents’ Post-Trial Answering Br. 38.

37
out of the merger. Thus, they assert that I should use “the expected capital structure

of the target company as a going concern.”207 The Petitioners point out that the

warrants had, in fact, been exercised prior to the date of the merger; the exercise was

not contingent or directly tethered to the merger itself, and the resulting shares were

voted in favor of the merger. Logic, equity, and precedent, they argue, require the

exercise of the warrants to be considered part of the operative reality of SWS.

The exclusion of changes in value resulting from the “accomplishment or

expectation” of the merger is applied narrowly. It is applied properly where the

change in the company is directly tied to merger.208 Here, two creditors made the

economic decision to exercise warrants in advance of the merger, and prior to the

record date, in order to vote those shares in favor of the merger. That is, this case is

unlike certain other decisions of this Court which look to actions taken by the subject

company, with an eye towards the merger, that changed the company’s balance

sheet.209 Here, I note, the warrant shares are included in both parties’ calculations

of the total number of shares outstanding over which to divide SWS’s total value in

207
Id. at 40.
208
See, e.g., Cede & Co. v. JRC Acq. Corp., 2004 WL 286963, at *7–8. (Del. Ch. Feb. 10, 2004)
(excluding debt incurred to finance a merger, and distinguishing a case that included transactions
with some relation to a merger as part of the “operative reality” where those transactions were in
place at the time of the merger).
209
See BMC Software, Inc., 2015 WL 6164771, at *13 (excluding excess cash the company
conserved in contemplation of the merger); Gearreald v. Just Care, Inc., 2012 WL 1569818, at *8
(Del. Ch. Apr. 30, 2012) (employing the theoretical capital structure the company would have
maintained as a going concern where the company paid off all of its debt only “as a condition of
the Merger Agreement”).

38
the per-share value calculation.210 I find the operative reality as of the date of the

merger was that the warrants were exercised three months prior to close, by third

parties acting in their own self-interest, and that the exercise was part of the

Company’s operative reality as of the merger date.

ii. Excess Regulatory Capital

The Petitioners argue that “excess capital must be valued separately as a

matter of law” and accounted for in a valuation.211 It is true that excess cash not

being redeployed into the business must be added to the result of the DCF

valuation.212 The Petitioners argue the same is true for excess regulatory capital in

the context of a bank holding company.213 The Respondents counter that the

Petitioners are improperly conflating regulatory capital with freely distributable

cash, and improperly assuming that a massive distribution would have no effect on

the company meeting management projections, which do not envisage any such bulk

distributions.214

Here, the warrant exercise created some additional excess regulatory capital.

By regulatory capital I mean generally the ratio which federal regulators require

210
See JX002 at Ex. 8; JX004 at 34.
211
Petitioners’ Post-Trial Answering Br. 28 (relying, in part, on Gholl v. Emachines, Inc., 2004
WL 2847865, at *13 (Del. Ch. Nov. 24, 2004)).
212
See Gholl, 2004 WL 2847865, at *13 (observing that “in determining the fair value of a
corporation, excess cash must be added to the result of the DCF valuation”).
213
See Petitioners’ Post-Trial Answering Br. 28 (arguing that “in the context of a bank holding
company, Delaware law treats excess capital the same way” as excess cash).
214
See Respondents’ Post-Trial Answering Br. 31–37.

39
banks and bank holding companies to maintain between their capital and their

assets.215 Capital in this context is roughly equivalent to stockholder’s equity.216

The exercise of the warrants did not directly put a single cent into the company—

that money had already been received and deployed by the Company upon execution

of the Credit Agreement in 2011. Rather, exercise of the warrants worked a

capitalization change, cancelling $87.5 million in debt owed in exchange for issuing

over 15 million shares in consideration for cancelling the debt. That change

increased regulatory capital. It did not, necessarily, create excess capital in the sense

of “excess cash” or marketable securities beyond what was needed to run the

business to meet management projections.217

Clarke alters management projections by distributing to shareholders $87.5

million in year one of his projections (the year of the warrant conversion), and then

$30 million more in year three.218 Clarke’s valuation model, which distributes over

$117 million in three years, while assuming no impact on SWS’s ability to generate

215
See, e.g., JX005 at 13 (explaining that “[r]egulatory capital is a book-value-based measurement
that is specified by government regulators” and that it “is not the same as excess cash readily
available for distribution”).
216
See Trial Tr. 736:11–737:11 (Ruback) (explaining that what “excess capital means is that you
have more equity than required by regulators”); id. at 408:20–409:13 (Jeremy Ford) (explaining
that “excess capital is really the equity component, and it relates for these regulated businesses . .
.”).
217
See, e.g., id. at 205:17–206:19 (Chereck) (testifying to the impracticability of a dividend in
2014, and that the Company “needed that capital to support the growth that we were projecting . .
.”).
218
JX001 at Schedule 2-A.

40
cash flow, is hard to accept on its face: it assumes that SWS would distribute to

shareholders over half of its pre-merger market capitalization of $198 million with

no effect on the Company or its income. I also find Ruback’s approach, making no

alterations to distribute excess regulatory capital in light of the structural changes

resulting from exercise of the warrants, somewhat problematic. However, on the

record here, I am persuaded that his approach is correct given the treatment of cash

flows in the management projections. Importantly, management assumed a warrant

exercise in 2016, but they do not project excess cash distributable as a result.219

I have no way to judge, on the record, how much capital, if any, would actually

be distributable as of the merger date, January 1, 2015, without altering downward

management’s projections of cash flow as a result.220 Clarke’s $87.5 million

immediate distribution is linked to the warrant exercise.221 Management projections

were made on an assumption of a warrant exercise in July 2016.222 Thus

management’s projections included that transaction, yet declined to assume a bulk

distribution in projecting the Company’s cash flows. The record does not reflect any

219
See Trial Tr. 261:20–262:11 (Edge); id. at 16:19–17:9 (Sterling). See also Respondents’ Post-
Trial Opening Br. 20 (arguing that management projections rested on the “favorable assumption”
that “Oak Hill and Hilltop would exercise their warrants in July 2016”).
220
See, e.g., Tr. 252:14–253:15 (Edge) (testifying to the de-facto requirement in the Broker-Dealer
business of having $100 million in excess capital for counterparties to transact business with SWS,
and that counterparties would cut SWS off when they dropped below $100 million in excess
capital).
221
JX001 at 30.
222
See supra note 219.

41
persuasive reason to second-guess management’s implied judgment. Further, I find

it facially unreasonable to assume, as does Clarke, that such a distribution could be

made without effect on the Company’s ability to generate cash flow consistent with

the projections. In addition, the record makes me doubtful, in light of SWS’s recent

emergence from major regulatory intervention, and its continuing business line in a

highly regulated industry, that such a massive distribution would be possible from a

regulatory prospective.223

It is true as a matter of valuation methodology that non-operating assets—

including cash in excess of that needed to fund the operations of the entity—are to

be added to a DCF analysis.224 The Petitioners seem to conflate distributable cash

or assets with a balance sheet increase in regulatory capital as the result of the

conversion of debt to equity in the form of Hilltop and Oak Hill’s new shares. The

Petitioners rely on In re PNB Holding Co. Shareholders Litigation225 for the

proposition that excess regulatory capital must be accounted for in valuing a bank

holding company. I note that PNB rejected a lump-sum distribution as proposed by

Clarke’s valuation, however.226 Rather, the Court explained that there was “no basis

223
See, e.g., Trial Tr. 205:17–206:11 (Chereck) (testifying that in 2014 it would have been “very
difficult” to get permission from federal regulators to dividend bank capital up to the holding
company level).
224
See Gholl, 2004 WL 2847865, at *13 (explaining that non-operating assets should be added to
the valuation and that “excess cash must be added to the result of the DCF valuation”).
225
In re PNB Holding Co. Shareholders Litig., 2006 WL 2403999 (Del. Ch. Aug. 18, 2006).
226
Id. at *26–28 (Del. Ch. Aug. 18, 2006) (“Despite its high Tier-1 Ratio as of the Merger date,
though, there is no basis in equity to assume that [the bank] was required to premise the Merger

42
in equity” to add to the DCF calculation a one-time dividend of excess regulatory

capital.227

For the reasons above, I defer to management projections, which assume a

warrant exercise in July 2016. In light of the fact that the operative reality here is

that the warrants were exercised earlier than implied in those projections, however,

other adjustments are proper, as discussed directly below.

c. Interest Expense Adjustments

Because the warrant exercise occurred earlier than management expected in

its projections, I do find it appropriate to reduce the interest expense accordingly to

reflect the Company’s operative reality. That is, management projections assumed

a warrant exercise in July 2016, implying interest payable through that date. Interest

expense for the gap between actual and projected exercise must be backed out

accordingly.

price on a reduction of its starting Tier-1 Ratio.”). The other case relied upon by the Petitioners,
in support of the major lump sum distribution advanced here, involved a discounted net income
analysis of a small community bank where both experts agreed it was proper to distribute certain
excess capital, and only disagreed as to the amount. See Petitioners’ Post-Trial Answering Br. 28
n.133 (citing Dunmire v. Farmers & Merchants Bancorp of W. Pa., Inc., 2016 WL 6651411, at
*16 (Del. Ch. Nov. 10, 2016)).
227
In re PNB, 2006 WL 2403999, at *26–27. I note the PNB Court observed, in rejecting a large
lump-sum distribution, that “it also is inappropriate to assume that PNB would retain cash simply
to remain well above the well-capitalized threshold.” Id. The PNB Court handled the excess
regulatory capital issue by distributing income in the future, and only retaining the amount required
to remain at what the Court set as a reasonable capitalization level. Id. The evidence on which to
perform a similar calculation here is lacking on this record.

43
 The warrant exercise removed $87.5 million in debt which was owed at an

8% interest rate. This adjustment results in the removal of $7 million in interest

expense for 2015, and $4.027 million for 2016.228 Given the assumed tax rate of

35%,229 this reduction in interest expense has the effect of increasing net income by

$4.6 million in 2015 and $2.6 million in 2016.230 Accordingly, I add these to the

management projections of net income in those two years.231

2. The Terminal Value Growth Rate

Clarke employed a 3.00% terminal growth rate after performing his

recommended adjustments to management projections. Ruback set his terminal

growth rate slightly higher, at 3.35%, which he derived from the midpoint of the

long term-expected inflation rate of 2.3% and the long-term expected economic

growth rate of the economy at large of 4.4%.232 Ruback’s rate was set without the

major adjustments to Company cash flows performed by Clarke. In his rebuttal

228
See JX001 at Schedule 2-D.
229
Id. See also JX005 at 16 n.51.
230
JX005 at 16 n.51. See also JX004 at 20 (indicating alterations to the interest expense result in
an additional few cents per share). I note that there is some apparent confusion or disagreement
as to the proper tax treatment of this reduction in interest expense. See JX004 at 9-C (adjusting
net income by $7 million in 2015, but only $2.618 million in 2016, and including a $6.791 million
tax expense in 2016). I find the approach I employed above the line reasonable here, and adopt it.
231
That is, I add 4.6 million and 2.6 million into cells A1 and B1, respectively, of Ruback’s model.
JX002 at Ex. 7.
232
Id. at 12.

44
report Clarke accepts Ruback’s growth rate as reasonable.233 On the facts here, I

adopt 3.35% as the proper terminal growth rate.

3. The Proper Discount Rate

Both parties and their experts rely on the Capital Asset Pricing Model

(“CAPM”) to calculate the cost of equity. The basic CAPM formula employed here

is the risk free rate, plus the product of beta times the equity risk premium, plus the

size premium.234 The parties and their experts agree that the risk free rate of return

is 2.47%, but disagree as to the three other inputs: the equity risk premium (“ERP”),

equity beta, and size premium.

a. Equity Risk Premium

The skirmish over this input is whether historical ERP or supply-side ERP is

the proper method for calculating ERP. The Respondents concede that recent

decisions of this Court have adopted supply-side ERP, but observe that ERP must

be decided on the facts of each case.235 Here, Ruback used an ERP of 7.0% which

represents the applicable historical ERP. Clarke, in contrast used the supply-side

ERP of 6.21%. While there was vigorous debate on this issue, I find that the supply-

side ERP provided by Clarke is proper here.236 While it is true that a case-by-case

233
JX004 at 23.
234
That is: Risk Free Rate + (Beta * Equity Risk Premium) + Size Premium = Cost of Equity.
235
See Respondents’ Post-Trial Answering Br. 41.
236
See Glob. GT LP v. Golden Telecom, Inc., 993 A.2d 497, 517–18 (Del. Ch. 2010). See also In
re Orchard Enterprises, Inc., 2012 WL 2923305, at *19 (citing Golden Telecom and finding that

45
determination of ERP remains appropriate, here there is no basis in the factual record

to deviate from what this Court has recently recognized as essentially the default

method in these actions.237 Therefore the proper ERP here is 6.21%.

b. Beta

The experts also disagree as to the appropriate beta. Clarke employs a beta of

1.10, whereas Ruback uses a beta of 1.18.

Ruback derived his beta from SWS’s performance rather than peer returns,

which Clarke employed. The Respondents argue that the “peers” are not actually

peers.238 Thus, the Respondents argue that a more targeted, company-specific beta,

as employed by Ruback, is appropriate.239 Ruback used two years of SWS weekly

stock returns ending on January 3, 2014, that is, data from the two years preceding

the announcement of Hilltop’s initial offer.240 I cannot accept Ruback’s beta on this

record. Ruback’s measurement period covered times where a “merger froth” and

corresponding volatility were likely reflected in SWS’s trading and price.241

Conveniently for the Respondents, Ruback’s weekly two-year lookback period

the party advancing a historical risk-premium did “not provide[] me with a persuasive reason to
revisit the supply-side versus historical equity risk premium debate”).
237
See id. See also Gearreald, 2012 WL 1569818, at *10.
238
Respondents’ Post-Trial Answering Br. 44.
239
Id.
240
JX002 at 16–17.
241
See, e.g., Respondents’ Post-Trial Answering Br. 60 (arguing that “Petitioners are therefore
wrong to say that the merger froth in SWS’s stock is speculative, because the uncontroverted
evidence demonstrates that the market anticipated a synergies-driven deal for SWS, and likely one
involving Hilltop”).

46
reflects this; it yields a beta of 1.18, which is higher than the five-year monthly

lookback of 0.81 and the five-year weekly lookback of 1.09.242

The Respondents argue that Clarke “supplied no explanation for his beta.”243

Clarke, however, used multiple data points:244 he surveyed possible betas and

concluded a blended median was proper.245 Clarke’s beta was derived in part,

however, with reference to companies that were not closely comparable.246

Clarke’s beta has drawbacks, then, including the extent of comparability to

SWS of the entities from which he derived it. Nonetheless, under the facts here I

find it best comports with the record. Therefore, I adopt Clarke’s beta of 1.10.

c. Size Premium

The experts agree that a size premium is appropriate here and that Duff &

Phelps is the appropriate source to employ to estimate the size premium. However,

they disagree as to which size premium should be used. Clarke uses a size premium

of 2.69%, whereas Ruback uses a size premium of 4.22%.

242
JX001 at Schedule 3-B. See also In re Appraisal of DFC Glob. Corp., 2016 WL 3753123, at
*10 (observing that “[a] five-year period is the most common for measuring beta and generally
results in a more accurate measurement, although two-year periods are used in certain
circumstances”).
243
Respondents’ Post-Trial Answering Br. 46.
244
See JX001 at 33.
245
Trial Tr. 541:21–543:22 (Clarke) (testifying to how he derived his beta and explaining that “I
think it's appropriate, when looking at beta, to get as many measurements as you can, to try to
triangulate something that is supportable both by the company itself and by peers”). See also
JX001 at Schedule 3-B.
246
See JX001 at Schedule 3-B.

47
 The divergence arises from the overall valuation of the company. Each expert

took a different approach to derive the appropriate “decile” which thereby provides

the size premium. Ruback selected the size premium based on the market

capitalization of SWS prior to Hilltop’s offer, which was approximately $198.5

million.247 Clarke performed calculations to arrive at a preliminary valuation based

on his DCF and other metrics, and used that value of $464 million to select the size

premium for the decile in that range.248 Ruback’s approach places SWS in a decile

that runs from approximately $190 million to $301 million, 249 whereas Clarke’s

approach places SWS in a decile that runs from $301 million to $549 million.250

The Respondents point out that Clarke’s approach is “circular,” and that his

approach is only “occasionally used” for computing size premiums for private

companies where market capitalization is not easily derived or reliable.251 Recent

cases in this Court, I note, are consistent with the criticism of Clarke’s approach in

selecting a size premium in valuing this public company.252 The Petitioners counter

247
JX002 at 17; JX005 at 19. I note this market capitalization figure excludes the warrant exercise
which I have found was part of the Company’s operative reality.
248
See JX001 at 34.
249
JX002 at 17.
250
JX001 at 34.
251
Respondents’ Post-Trial Answering Br. 47–48.
252
See, e.g., Merion Capital, L.P. v. 3M Cogent, Inc., 2013 WL 3793896, at *19 (Del. Ch. July 8,
2013) (observing that the “Court of Chancery consistently has used market capitalization as the
benchmark for selecting the equity size premium”). See also In re Appraisal of DFC Glob. Corp.,
2016 WL 3753123, at *14 (observing that “the size premium itself is calculated using market
value, when available, as it is here”).

48
that while using market capitalization is generally appropriate for public companies,

the “capital structure” here (including the large amount of outstanding warrants—

17,391,304—where the total shares outstanding were only 32,747,990) makes the

market capitalization approach imperfect and inappropriate.253 They contend that

SWS has enough in common with a private company for an iterative calculation to

be appropriate.254 Both sides have presented some support for their respective size

premiums that I find persuasive. SWS was a public company thus making it

generally susceptible to Ruback’s market capitalization approach. However, it had

a substantial amount of in-the-money warrants and significant influence by certain

major creditors—making it in some ways more analogous to a private company. I

find it appropriate in these circumstances to use the midpoint of these approaches,

and I find the applicable size premium is 3.46%.

III. CONCLUSION

For the reasons stated above, and using the valuation inputs I have described,

I find the “fair value” of the Petitioners shares of SWS as of the date of the merger

was $6.38. The Petitioners are entitled to the fair value of their shares together with

interest at the statutory rate. I note that the fact that my DCF analysis resulted in a

value below the merger price is not surprising: the record suggests that this was a

253
Petitioners’ Post-Trial Answering Br. 50.
254
Id. at 50–51.

49
synergies-driven transaction whereby the acquirer shared value arising from the

merger with SWS.

The parties should confer and provide a form of order consistent with this

Memorandum Opinion.

50